Clinicopathologic characteristics substratified by tumour location
| Characteristic | Junctional tumours; no. (%) of patients* | Gastric tumours; no. (%) of patients* | ||||
|---|---|---|---|---|---|---|
| pMMR n = 83 | dMMR n = 15 | p value | pMMR n = 52 | dMMR n = 13 | p value | |
| Age, mean ± SD, yr | 66 ± 9 | 72 ± 11 | 0.02 | 68 ± 12 | 75 ± 16 | 0.1 |
| Male sex | 63 (76) | 10 (67) | 0.7 | 36 (69) | 10 (77) | 0.8 |
| Clinical stage | ||||||
| Early (I–II) | 14 (17) | 6 (40) | 0.09 | 25 (48) | 2 (15) | 0.07 |
| Locally advanced (III) | 69 (83) | 9 (60) | 27 (52) | 11 (85) | ||
| Neoadjuvant therapy | ||||||
| None | 18 (22) | 7 (47) | 0.07 | 31 (60) | 5 (38) | 0.4 |
| Chemotherapy | 63 (76) | 7 (47) | 21 (40) | 6 (46) | ||
| Chemoradiotherapy | 2 (2) | 1 (7) | 0 (0) | 0 (0) | ||
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (15) | |
| Tumour grade | ||||||
| Well differentiated | 3 (4) | 2 (13) | 0.3 | 1 (2) | 1 (8) | 0.2 |
| Moderately differentiated | 35 (42) | 6 (40) | 18 (35) | 7 (54) | ||
| Poorly differentiated | 45 (54) | 7 (47) | 33 (63) | 5 (38) | ||
| Pathologic stage | ||||||
| I | 5 (6) | 4 (27) | 0.04 | 11 (21) | 3 (23) | 0.4 |
| II | 9 (11) | 3 (20) | 14 (27) | 6 (46) | ||
| III | 54 (65) | 7 (47) | 23 (44) | 4 (31) | ||
| IV | 15 (18) | 1 (7) | 4 (8) | 0 (0) | ||
| No. of positive lymph nodes, median (IQR) | 4 (2–12) | 1 (0–3) | 0.005 | 2 (0–6) | 1 (0–9) | 0.6 |
| Lymph node status | ||||||
| N0 | 10 (12) | 7 (47) | 0.008 | 15 (29) | 6 (46) | 0.5 |
| N1 (1–2) | 17 (20) | 2 (13) | 12 (23) | 2 (15) | ||
| N2 (3–6) | 22 (26) | 4 (27) | 13 (25) | 1 (8) | ||
| N3 (≥ 7) | 34 (41) | 2 (13) | 12 (23) | 4 (31) | ||
| Survival analysis | ||||||
| 90-day mortality | 8 (10) | 3 (20) | 0.5 | 2 (4) | 0 (0) | 0.9 |
| Overall survival, median (95% CI), yr† | 1.9 (1.3–2.6) | 4.6 (3.4–5.9) | 0.008 | 3.0 (2.2–6.7) | 5.6 (1.9–9.3) | 0.6 |